A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

Inclusion Criteria:

- Healthy male and female participants (healthy status is defined by the absence of
evidence of any active or chronic disease following a detailed medical and surgical
history, a complete physical examination including vital signs, 12-lead
electrocardiogram, hematology, blood chemistry, coagulation, serology, and urinalysis)

- Body mass index between 18.0 and 30.0 kilograms per meter squared (kg/m^2), inclusive

- Female participants of childbearing potential must commit to use two acceptable forms
of contraception during the study and until at least 6 months after the follow-up
visit

Exclusion Criteria:

- History of any clinically significant gastrointestinal, renal, hepatic,
broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological,
hematological or allergic disease, metabolic disorder, cancer, or cirrhosis

- History or suspicion of drugs of abuse or alcohol addiction

- Smokers who smoke more than 10 cigarettes per day or equivalent amount of tobacco as
determined by history

- Pregnant or lactating women

- Positive result on hepatitis B virus (HBV), hepatitis C virus (HCV), or Human
immunodeficiency virus (HIV)-1 and -2

- Any familial history of early onset Alzheimer's disease

- Prior administration of gantenerumab

- Participation in an investigational drug medicinal product or medical device study
within 90 days before dosing or within seven times the elimination half-life,
whichever is longer

- Any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or
lesions in the area intended for SC injection